JAK2 and lymphoma: It should also be noted that whether JAK2 inhibitors are associated with an increased risk of lymphomagenesis remains equivocal, as the observational studies by Pemmaraju et al. [20] and Rumi et al. [21] did not show an increased risk of lymphoma in patients treated with these agents compared to those alternatively treated.